AstraZeneca Notches Another Indication for Imfinzi, Pushing PD-L1 Blocker Into Stomach Cancer

By /

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

Scroll to Top